PCM
PACB icon

Prelude Capital Management’s Pacific Biosciences PACB Stock Holding History

Prelude Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40,000
Closed -$1.4M – 1951
2021
Q2 		$1.4M Hold
40,000
– – 0.04% 444
2021
Q1 		$1.33M Buy
+40,000
New +$1.4M 0.03% 494

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Prelude Capital Management's PACB Position: Q4 2024 in Review

Prelude Capital Management sold out of Pacific Biosciences (PACB) in Q4 2024, closing a stake of 16,800 shares — an estimated $28.6K sold.

Prelude Capital Management first reported a position in PACB in Q3 2014 and held it in 24 quarters. The position peaked at $2.21M in Q2 2021. 226 funds tracked by Wall St. Rank hold PACB as of Q4 2024.

  • Prelude Capital Management reported no remaining Pacific Biosciences position as of Q4 2024 after selling out during the quarter.
  • Prelude Capital Management sold 16,800 Pacific Biosciences shares in Q4 2024, an estimated $28.6K.
  • Prelude Capital Management first reported a position in Pacific Biosciences in Q3 2014 and held it in 24 quarters.
  • Prelude Capital Management's Pacific Biosciences position peaked at $2.21M in Q2 2021.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2024.

Based on Prelude Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.